logo-loader
viewClinigen Group PLC

Clinigen and Bristol-Myers Squibb sign extended partnership agreement in South Africa

Clinigen and Bristol-Myers Squibb sign extended partnership agreement in South Africa

Shaun Chilton, CEO of Clinigen Group PLC (LON:CLIN) tells Proactive that agreement with Bristol-Myers Squibb proves two things.

“One, that pharmaceutical companies, even the biggest ones, are looking to partner in certain parts of the world in terms of commercialising their medicines,“ Shaun Chilton said.

He added: “And also I think it proves that we have built an infrastructure particularly in Africa, using South Africa as a hub, that makes it a very attractive partner to pharmaceutical companies.”

Quick facts: Clinigen Group PLC

Price: 700.5 GBX

AIM:CLIN
Market: AIM
Market Cap: £930.96 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Inspiration Healthcare CEO pleased with 30% growth in first half revenues

Inspiration Healthcare Group PLC's (LON:IHC) Neil Campbell tells Proactive he's confident they'll achieve market expectations for the full year after a strong first half. Underlying revenues in the six months to the end of July, 2020, were up by around 30% on the corresponding period of last...

28 minutes ago

2 min read